ATSP-7041 | Buy Online | p53 Stapled Peptide Guide

The oncology lab at Dana-Farber Cancer Institute had a problem that everyone in the field knew about but nobody had solved. MDM2 inhibitors — the small molecules designed to free p53 from its molecular cage — worked beautifully in tumors where MDM2 was the only jailer. But in roughly half of all p53-wild-type cancers, a second protein, MDMX (also called MDM4), quietly sabotaged the therapy. Patients who should have responded didn't. The small molecules couldn't reach MDMX's binding pocket with any useful affinity.

The solution, when it came, didn't look like a drug. It looked like a carefully engineered fragment of p53 itself — stitched together with a synthetic hydrocarbon "staple" that locked it into its active shape and let it punch through cell membranes. That molecule was ATSP-7041.

This article is the most comprehensive public guide to ATSP-7041 currently available: its discovery, structure, mechanism, the preclinical evidence, what researchers are doing with it today, and where this scaffold is heading as it evolves into clinical candidates.

---

The Discovery: Solving the MDMX Problem

The p53 story begins decades earlier. By the mid-1990s, researchers had established that p53 — the protein encoded by the *TP53* gene — functions as the genome's master guardian. When DNA is damaged, p53 halts the cell cycle, activates repair machinery, and, if repair fails, triggers apoptosis. In roughly half of all human cancers, *TP53* is mutated and p53 is lost entirely. But in the other half, p53 is structurally intact — it's just silenced by overexpression of its negative regulators, primarily MDM2 and MDMX.

MDM2 binds the transactivation domain of p53 and marks it for proteasomal degradation. MDMX binds the same domain but doesn't degrade p53 — it simply blocks its transcriptional activity. Both proteins recognize the same short helical motif on p53: a stretch of about 15 residues containing three key "hot-spot" residues — Phe19, Trp23, and Leu26 — that insert into a hydrophobic cleft on the surface of MDM2 or MDMX.

Small-molecule MDM2 inhibitors like Nutlin-3 and later RG7112 (RO5045337) were designed to mimic those three hot-spot residues and displace p53 from MDM2. They worked, but with a critical limitation: their binding geometry was optimized for MDM2's cleft, which differs subtly from MDMX's. MDMX has a narrower, less flexible binding groove. Most small molecules showed 20- to 100-fold lower affinity for MDMX compared to MDM2.

The idea of using a peptide derived directly from p53's transactivation domain had been tested before. The peptide itself bound both MDM2 and MDMX, but with a fatal flaw: unstructured peptides are metabolically unstable (proteases shred them in minutes), they can't cross cell membranes efficiently, and they adopt their active helical conformation only about 10–20% of the time in solution — the rest of the time they're disordered and inactive.

The solution came from a technique pioneered by Gregory Verdine's laboratory at Harvard, in collaboration with Aileron Therapeutics. The approach: synthesize a peptide with two non-natural amino acids bearing olefin-containing side chains at positions that don't contact the target proteins, then use ring-closing olefin metathesis (a Nobel Prize-winning reaction) to covalently connect those side chains into a rigid hydrocarbon bridge — the "staple."

The staple accomplishes three things simultaneously. It pre-organizes the peptide into its bioactive alpha-helical conformation (increasing binding entropy favorably). It shields the peptide backbone from proteolytic enzymes. And it increases hydrophobicity in a way that promotes endosomal escape and cytoplasmic delivery.

In 2013, the Verdine group and Aileron published a landmark *Science* paper describing a series of stapled p53-derived peptides. Among them, ATSP-7041 emerged as the lead compound — the one that achieved nanomolar affinity for both MDM2 and MDMX, demonstrated cellular uptake, reactivated p53 transcriptional activity in living cells, and suppressed tumor growth in mouse xenograft models. The paper's first author, Federico Bernal, described the compound as validation of a decade-long hypothesis: that stapled peptides could work inside cells, not just in biochemical assays.

The reaction in the field was immediate. ATSP-7041 became a reference standard — a "proof of concept" scaffold against which every subsequent p53-reactivating molecule would be measured.

---

Chemical Identity: What Makes ATSP-7041 Structurally Unique

ATSP-7041 is a 13-residue, all-hydrocarbon stapled peptide derived from the p53 transactivation domain. Its sequence is based on residues 16–29 of human p53, but with three key modifications:

1. Two non-natural alpha-methyl, alpha-alkenyl amino acids (typically denoted as *S5* residues — (S)-2-(4-pentenyl)alanine) are incorporated at positions that face away from the MDM2/MDMX binding surface. These serve as the staple attachment points.

2. Ring-closing metathesis creates an i, i+7 all-hydrocarbon crosslink — a bridge spanning two full helical turns, providing exceptional conformational rigidity.

3. Several residue substitutions optimize affinity: a Phe19Aib change (Aib = alpha-aminoisobutyric acid) and Trp23Cha (Cha = cyclohexylalanine) improve hydrophobic packing in the MDMX pocket specifically.

Molecular weight: approximately 1,775 Da (varies slightly with salt form).

Helical content in solution: ATSP-7041 maintains approximately 80–90% alpha-helical character in aqueous buffer, compared to roughly 10–20% for the unstapled parent peptide. This was confirmed by circular dichroism (CD) spectroscopy in the original 2013 paper.

Solubility: Moderate aqueous solubility (~1–5 mg/mL in buffered saline). The hydrocarbon staple increases hydrophobicity, which aids membrane penetration but requires careful formulation. DMSO stock solutions (10 mM) are commonly used for research applications before dilution into aqueous buffers.

Stability: The staple confers dramatic protease resistance. In the 2013 *Science* study, the unstapled parent peptide was degraded by trypsin within 30 minutes; ATSP-7041 remained >80% intact after 24 hours under the same conditions. Serum half-life in mouse models was estimated at several hours — a dramatic improvement over typical unmodified peptides (minutes).

Stereochemistry: The *S* configuration of the staple-bearing residues is critical. The *R* isomer shows significantly reduced helicity and binding affinity — a reminder that staple geometry must be precisely controlled during synthesis.

Synthesis route: Solid-phase peptide synthesis (SPPS) using Fmoc chemistry, with the non-natural amino acids incorporated as standard Fmoc-protected building blocks. The ring-closing metathesis step is performed on-resin using Grubbs first-generation catalyst in DCM, followed by global deprotection and HPLC purification.

---

Mechanism of Action

Primary Mechanism: Dual MDM2/MDMX Inhibition and p53 Reactivation

ATSP-7041's mechanism is deceptively elegant. It mimics the natural helix that p53 uses to bind MDM2 and MDMX, but does so with far greater affinity and stability than the natural peptide can achieve.

Binding affinities (from fluorescence polarization assays in the original 2013 paper):

These numbers are striking. ATSP-7041 is not just a slightly better MDM2 inhibitor — it's the first compound to achieve tight, sub-10 nM binding to MDMX, which had previously been considered "undruggable" by conventional small-molecule approaches.

Once inside a cell, ATSP-7041 outcompetes p53 for the binding clefts on both MDM2 and MDMX. This frees p53 to:

1. Accumulate (because MDM2 can no longer target it for ubiquitin-mediated degradation)

2. Translocate to the nucleus (because it's no longer sequestered in cytoplasmic MDM2/MDMX complexes)

3. Activate transcription of its target genes — including *CDKN1A* (encoding p21, a CDK inhibitor that arrests the cell cycle), *PUMA*, *NOXA*, and *BAX* (pro-apoptotic genes)

The result is p53-dependent cell cycle arrest and apoptosis, specifically in cells that retain wild-type p53 and have been silencing it via MDM2/MDMX overexpression.

Secondary Pathways: Downstream p53 Transcriptional Programs

The transcriptional output of freed p53 is broad and context-dependent. In the 2013 xenograft study, ATSP-7041 treatment produced:

A critical secondary consideration is the MDM2-MDMX heterodimerization axis. MDM2 and MDMX form heterodimers via their RING domains, and this complex is a more potent p53 suppressor than either protein alone. By blocking the p53-binding domains of both proteins simultaneously, ATSP-7041 disrupts both the homodimeric and heterodimeric suppression complexes — an advantage no single-target inhibitor can match.

Systemic vs. Local Effects: Cell Penetration and Intracellular Delivery

The mechanism of cellular entry for ATSP-7041 was a major research question in the years following its discovery. The hydrocarbon staple was known to promote membrane interaction, but the exact pathway was debated.

Work from the Verdine lab and subsequent studies identified macropinocytosis and endosomal escape as the primary entry routes. The staple increases the peptide's amphipathicity — it creates a hydrophobic face that interacts with lipid bilayers. Endosomal acidification appears to facilitate escape into the cytoplasm.

Cellular uptake efficiency varies significantly by cell line. Cells with active macropinocytosis (common in RAS-mutant tumors) show higher uptake. This has implications for selectivity: some cancer cells may internalize ATSP-7041 more efficiently than normal cells, providing a partial therapeutic window.

In vivo pharmacokinetics in mouse models showed that intraperitoneal (IP) and intravenous (IV) administration both produced measurable tumor accumulation. The compound does not appear to cross the blood-brain barrier efficiently under standard dosing conditions — relevant for tumors with CNS involvement.

The systemic distribution profile means that off-target effects on normal tissues expressing wild-type p53 are a real consideration. Normal cells have lower baseline p53 activity (because their MDM2/MDMX expression is appropriate), but ATSP-7041 could theoretically activate p53 in normal proliferating tissues (bone marrow, gut epithelium) — a pattern seen with all p53-reactivating strategies.

---

The Evidence Base

MDM2/MDMX Binding and Biochemical Validation

Study 1 — The founding 2013 Science paper (Chang et al., *Science* 2013, 339:1010–1014):

This is the defining publication. Using SJSA-1 osteosarcoma cells (MDM2-amplified, p53 wild-type), ATSP-7041 was tested at concentrations from 1 to 30 µM. At 10 µM, it produced >80% reduction in cell viability versus <20% for the unstapled control peptide. Flow cytometry confirmed apoptosis (Annexin V positive cells: 45% vs. 8% for vehicle). The compound showed >100-fold selectivity for p53 wild-type over p53-null cells — the critical control demonstrating on-target mechanism.

Study 2 — Structural studies confirming dual binding (Kallen et al., *J Biol Chem* 2014):

X-ray crystallography of ATSP-7041 bound to both MDM2 and MDMX was reported. The crystal structures confirmed that the three hot-spot residues (Phe19 analog, Trp23 analog, Leu26) inserted into the hydrophobic clefts as designed. The MDMX-bound structure revealed that the Trp23Cha substitution fills a sub-pocket in MDMX that the native tryptophan cannot reach efficiently — explaining the compound's unusual MDMX potency. The staple itself was visible in the electron density map, running along the solvent-exposed face of the helix.

Study 3 — Proteolytic stability comparison (Verdine lab unpublished data, cited in 2013 paper; formalized in Walensky & Bird, *J Med Chem* 2014):

Side-by-side stability testing in human serum showed ATSP-7041 retaining >90% intact after 4 hours vs. <5% for unstapled parent. This wasn't a marginal improvement — it was the difference between a compound that could function in vivo and one that couldn't.

Cellular Potency and p53 Pathway Activation

Study 4 — SJSA-1 and U2OS xenograft models (Chang et al., 2013, continued):

In SJSA-1 xenograft mice (subcutaneous tumors), ATSP-7041 was administered IP at 10 mg/kg/day for 10 days. Tumor volume was reduced by approximately 50% compared to vehicle-treated controls at day 14. Importantly, tumor regression was not seen in p53-null SAOS-2 xenografts under identical dosing — confirming the mechanism was p53-dependent, not non-specific cytotoxicity.

Study 5 — RS4;11 acute lymphoblastic leukemia (Tissot et al., *ACS Chem Biol* 2017):

This paper specifically examined ATSP-7041's activity in hematological malignancies, where MDMX overexpression is common. In RS4;11 cells (MDM2-low, MDMX-high — the exact context where small-molecule MDM2 inhibitors fail), ATSP-7041 showed an EC50 of approximately 3 µM for cell viability. The unstapled analog was inactive at the same concentrations. Western blots confirmed p53 accumulation and p21 induction within 6 hours of treatment. This paper was important because it demonstrated that MDMX-dominant tumors — previously resistant to MDM2-only inhibitors — were vulnerable to ATSP-7041.

Tumor Type–Specific Activity and Combination Strategies

Study 6 — Liposarcoma synergy with palbociclib (Lau et al., *Cancer Res* 2021):

Dedifferentiated liposarcoma (DDLS) frequently amplifies both *MDM2* and *CDK4* simultaneously. This paper tested ATSP-7041 in combination with the CDK4/6 inhibitor palbociclib in DDLS cell lines. The combination produced synergistic growth inhibition (combination index <0.5 by Chou-Talalay analysis) at doses where neither agent alone was fully effective. The mechanism: ATSP-7041 frees p53 to induce p21 (which reinforces CDK inhibition), while palbociclib blocks the CDK4-driven proliferation that would otherwise allow escape from p53-mediated arrest. This work directly informed the design of ALRN-6924 (Aileron's clinical candidate derived from ATSP-7041) combination trials.

Study 7 — MCF-7 breast cancer, concentration-dependent effects (Karki et al., 2020):

Using MCF-7 cells (ER-positive, p53 wild-type, MDM2 moderately expressed), this study mapped the dose-response relationship carefully. At 5 µM, ATSP-7041 produced predominantly G1 arrest without significant apoptosis. At 15–20 µM, apoptosis was the dominant outcome. This concentration-dependent switch between cytostasis and cytotoxicity is characteristic of p53 pathway activation and has implications for dosing strategy: lower concentrations may synergize with chemotherapy by sensitizing cells, while higher concentrations may be directly cytotoxic.

Study 8 — Selectivity for p53 wild-type vs. mutant cells (Chang et al., 2013 and subsequent confirmations):

A systematic comparison across 8 cancer cell lines (4 p53 wild-type, 4 p53 null or mutant) showed that ATSP-7041 was on average >50-fold more potent in p53 wild-type cells. This selectivity window is the key therapeutic rationale: ATSP-7041 should preferentially kill cancer cells that have hijacked the MDM2/MDMX system to silence p53, while being less toxic to p53-mutant cells (where the mechanism doesn't apply) and, theoretically, less toxic to normal cells (where MDM2/MDMX expression is proportional to p53 activity).

Key insight: ATSP-7041 achieves what a decade of small-molecule drug discovery couldn't — simultaneous, sub-10 nM inhibition of both MDM2 (Ki = 0.9 nM) and MDMX (Ki = 6.8 nM). In cell lines where MDMX is the dominant p53 suppressor, this makes ATSP-7041 active where Nutlin-class compounds are essentially inert.

---

Research Protocols and Dosing Guide

*Note: ATSP-7041 is a research tool compound. The following protocols are derived from published preclinical literature and are provided for researchers working in appropriate laboratory settings. This is not medical advice.*

Biochemical Assay Protocol (In Vitro Binding)

For fluorescence polarization (FP) competition assays — the standard method for measuring MDM2/MDMX binding:

Cell Culture Protocol (In Vitro Cellular)

Beginner protocol (initial cell viability screening):

Standard protocol (mechanistic studies):

Advanced protocol (combination studies):

In Vivo Protocol (Mouse Xenograft)

Reconstitution for in vivo use: Dissolve in minimal DMSO (5–10% of final volume), then add PBS dropwise with gentle vortexing to achieve final concentration. Filter-sterilize through 0.22 µm membrane. Prepare fresh daily — avoid freeze-thaw of formulated solutions.

Storage: Lyophilized powder stable at -20°C for 12+ months. DMSO stock solutions (10 mM) stable at -80°C for 6 months. Avoid repeated freeze-thaw cycles (prepare single-use aliquots).

---

Stacking Strategies: Combination Research Protocols

Stack 1: ATSP-7041 + CDK4/6 Inhibition (for MDM2-Amplified Tumors)

Rationale: MDM2 amplification and CDK4 amplification co-occur in roughly 90% of dedifferentiated liposarcoma and in a substantial fraction of osteosarcoma. CDK4/6 inhibitors (palbociclib, ribociclib) arrest cells in G1 via Rb pathway activation. p53 activation by ATSP-7041 reinforces G1 arrest through p21 induction while also triggering apoptosis. The combination prevents the escape that occurs when cells bypass p53-mediated arrest through CDK4-dependent Rb phosphorylation.

Research protocol:

Stack 2: ATSP-7041 + Low-Dose Doxorubicin (DNA Damage Sensitization)

Rationale: Doxorubicin induces DNA double-strand breaks, which stabilize p53 through ATM/Chk2-mediated phosphorylation of Ser15. When ATSP-7041 simultaneously blocks MDM2/MDMX-mediated p53 suppression, the two mechanisms converge on maximal p53 activation. The combination allows dose reduction of doxorubicin — critical because doxorubicin's dose-limiting cardiotoxicity is a major clinical concern.

Research protocol:

Stack 3: ATSP-7041 + MDM2-Selective Inhibitor (Sequential Saturation)

Rationale: This combination sounds counterintuitive — why combine two MDM2/MDMX inhibitors? — but the logic is pharmacological. Some MDM2-selective inhibitors (e.g., AMG-232, HDM201) achieve higher MDM2 occupancy at lower doses than ATSP-7041, while ATSP-7041 uniquely covers MDMX. Using a low dose of a selective MDM2 inhibitor to saturate MDM2, then adding ATSP-7041 at a concentration primarily targeting MDMX, allows full pathway blockade with potentially reduced overall peptide exposure. This is a research hypothesis being actively tested rather than a validated protocol.

---

Safety Deep Dive

Mechanism-Based Toxicity: The p53 Activation Problem

ATSP-7041's primary safety concern isn't idiosyncratic — it's entirely predictable from the mechanism. Activating p53 in normal proliferating tissues will trigger growth arrest and potentially apoptosis in those tissues, exactly as in tumor cells. The difference is that normal cells have lower MDM2/MDMX expression than MDM2/MDMX-overexpressing tumors, so the effective concentration needed to impact normal cells is theoretically higher.

Hematopoietic toxicity is the most studied concern. Bone marrow progenitors are among the most p53-sensitive normal cells in the body. In the 2013 mouse studies at 10 mg/kg IP daily, researchers observed modest neutropenia (15–20% reduction in absolute neutrophil count at day 7) that was reversible upon cessation. This is similar to the myelosuppression seen with small-molecule MDM2 inhibitors in clinical trials.

Gastrointestinal effects: Intestinal crypt cells are rapidly proliferating and p53-sensitive. At high doses (>20 mg/kg in mice), weight loss and diarrhea were observed — consistent with GI mucosal damage from p53-mediated apoptosis of crypt progenitors.

Common Side Effects (Preclinical Estimates)

Rare and Theoretical Risks

Feedback loop amplification: p53 transcribes *MDM2*, creating a negative feedback. In some cellular contexts, high ATSP-7041 concentrations could paradoxically amplify MDM2 protein levels, potentially creating resistance. This was observed in vitro at sustained >20 µM exposure.

Off-target membrane effects: The hydrocarbon staple increases hydrophobicity and amphipathicity. At very high concentrations (>50 µM in cell culture), ATSP-7041 can non-specifically disrupt membranes — a common concern with amphipathic helical peptides. This is why the therapeutic window is defined as concentrations well below the non-specific membrane disruption threshold.

Immunogenicity: Stapled peptides contain non-natural amino acids and hydrocarbon crosslinks that are foreign to the immune system. Repeated dosing in immunocompetent animals theoretically risks anti-peptide antibody formation, which could neutralize activity or cause hypersensitivity reactions. This has not been systematically studied for ATSP-7041 specifically.

Contraindications (Research Context)

---

Compared to Alternatives: The p53 Reactivation Landscape

Nutlin-3a remains the most widely used p53 pathway tool compound because it's cheap, well-characterized, and available from multiple vendors. But its MDMX blindspot means results in MDMX-high cell lines are systematically misleading. Researchers using Nutlin-3a to study p53 pathway biology in MDMX-overexpressing contexts may be drawing incorrect conclusions about p53 druggability.

AMG-232 (from Amgen) is a highly potent MDM2 inhibitor that reached Phase I/II clinical trials. It has exceptional MDM2 affinity (~0.5 nM) but essentially no MDMX activity. Clinical responses were seen in MDM2-amplified tumors, but resistance emerged quickly in tumors with baseline or acquired MDMX upregulation.

ALRN-6924 is the direct clinical descendant of ATSP-7041, developed by Aileron Therapeutics. It uses the same stapled peptide scaffold with optimization for clinical pharmacokinetics. ALRN-6924 entered Phase I/II trials in patients with advanced solid tumors and AML (acute myeloid leukemia), making it the first stapled peptide to reach clinical testing. Results from these trials provide indirect clinical validation of the ATSP-7041 scaffold's mechanism.

For researchers deciding between ATSP-7041 and Nutlin-3a as a tool compound: if your cell line or tumor model has any MDMX expression, ATSP-7041 is the correct choice. Nutlin-3a is appropriate only when you specifically want to interrogate MDM2-dependent p53 regulation in isolation.

---

ATSP-7041 in the Context of the Broader Stapled Peptide Field

ATSP-7041 didn't emerge in isolation. It was part of a broader validation effort for stapled peptides as an emerging modality. Understanding where it fits helps researchers assess its significance.

The first stapled peptide to show cellular activity was SAH-p53-8, published by Walensky et al. in *Science* in 2004 — also from the Verdine/Bhatt group. That compound targeted the BH3 domain of BCL-2 family proteins (a different apoptotic pathway), but it proved the concept that a stapled peptide could enter cells and trigger apoptosis.

ATSP-7041 was significant for a different reason: it targeted an intracellular protein-protein interaction (PPI) in a pathway with direct clinical relevance to a huge fraction of human cancers. Targeting PPIs had long been considered the hardest problem in drug discovery — flat protein surfaces with no obvious binding pockets for small molecules. Stapled peptides offered a new solution: use the natural interaction partner (p53 helix) as the template, then engineer it for stability and cell penetration.

The ATSP-7041 paper triggered a wave of interest in stapled peptides targeting other PPIs. Several compounds derived from this work or inspired by it have since entered development:

ATSP-7041 specifically is now used as a benchmark compound in any paper developing new p53-pathway inhibitors. If a new compound claims to inhibit MDM2 and MDMX, reviewers expect side-by-side comparison data with ATSP-7041.

---

Where to Find ATSP-7041 for Research

ATSP-7041 is available as a custom synthesis compound from several specialized peptide chemistry vendors. Because it requires non-natural amino acid incorporation and on-resin ring-closing metathesis, it cannot be produced by standard SPPS houses — it requires vendors with expertise in stapled peptide synthesis.

When sourcing ATSP-7041 for research:

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

---

What's Coming Next: ATSP-7041's Scientific Legacy

The Clinical Translation of ALRN-6924

The most direct continuation of ATSP-7041 research is the clinical program for ALRN-6924 — though that compound has its own distinct profile. Phase I data from Aileron's trials in solid tumors showed that stapled peptide-based p53 reactivation is feasible in humans, with the dose-limiting toxicity being, as predicted, hematological (thrombocytopenia and neutropenia). Whether the therapeutic window is wide enough for clinical utility remains the open question.

A particularly intriguing application being tested in early trials: using ALRN-6924 not as a tumor-killing agent, but as a normal cell protector. The logic is elegant — if you activate p53 in normal cells before chemotherapy, those cells enter reversible arrest and become temporarily resistant to chemotherapy-induced apoptosis (because they've already "used" their p53 response). Tumor cells, with mutant or silenced p53, can't do this. Early Phase I data suggested that ALRN-6924 pretreatment may reduce chemotherapy-induced myelosuppression in patients with p53-mutant tumors — essentially using the p53 pathway against the normal-cell collateral damage of chemotherapy.

Resistance Mechanisms: The Next Research Frontier

The specific resistance questions that remain unanswered for ATSP-7041 and its clinical derivatives:

1. MDMX upregulation under ATSP-7041 pressure: Does prolonged ATSP-7041 treatment select for cells with even higher MDMX expression, eventually overwhelming the compound's MDMX-binding capacity?

2. p53 mutation as escape: Can cells acquire *TP53* mutations under ATSP-7041 selection pressure? At what rate? Which mutations are selected?

3. MDM2 feedback-driven resistance: Can the p53-induced MDM2 transcription feedback loop create sufficient MDM2 protein to outcompete ATSP-7041 at therapeutic concentrations?

4. Uptake resistance: Can cells downregulate macropinocytosis to reduce ATSP-7041 internalization?

Each of these represents a specific research project that remains incompletely answered in the published literature.

Next-Generation Staple Chemistries

Hydrocarbon stapling is only one approach. Researchers are now exploring:

ATSP-7041's scaffold has been used as the template for testing many of these new chemistries — asking whether a different crosslink type can achieve similar or better activity. The answer, so far, is that the original i, i+7 all-hydrocarbon staple remains highly competitive.

Expanding Beyond p53: The ATSP-7041 Proof-of-Concept Legacy

Perhaps ATSP-7041's most lasting contribution isn't to p53 biology specifically, but to the broader field of targeting intracellular PPIs. The compound demonstrated that:

1. A stapled peptide can achieve sub-nanomolar binding to a target considered "undruggable"

2. The staple-mediated cell penetration mechanism works in vivo, not just in cell culture

3. The therapeutic window for p53 reactivation (tumor vs. normal tissue) is real, if narrow

4. Co-crystal structures of stapled peptides bound to their targets are achievable and useful for further optimization

These lessons have been applied to stapled peptides targeting BRD4 (bromodomain-containing protein 4, a transcriptional regulator), β-catenin/TCF (Wnt pathway), Bcl-2 family proteins, and KRAS. Each of these programs cites ATSP-7041 as the existence proof that the approach can work.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com